Result of Preferential Subscription Rights Issue

RNS Number : 3966X
Novacyt S.A.
20 March 2026

Not to be distributed, directly or indirectly, in the United States, Australia, New Zealand, Canada, Japan, or South Africa, or any other jurisdiction in which the availability of the Offer (and any other transaction contemplated in connection therewith) would violate any applicable law or regulation (each a "Restricted Jurisdiction").

Novacyt S.A.

("Novacyt" the "Company" or the "Group")

Result of Preferential Subscription Rights Issue

Paris, France, and Manchester, UK - 20 March 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the result of its preferential subscription rights ("PSR") issue (the "Offer"). The purpose of this round of financing was to allow existing Shareholders to participate in an equity raise following the announcement of the completion of the acquisition of Southern Cross Diagnostics Pty Ltd ("SCD").

In total, the Company has raised €784,736 through the issue of 1,961,840 new ordinary shares ("New Shares"), which includes 1,041,348 shares representing €416,539.20 subscribed for by the former owner of SCD.

Lyn Rees, CEO of Novacyt, commented: *"Following the acquisition of SCD, which opened up new distribution channels to the life sciences and diagnostics industries in Australia and the wider Asia-Pacific region for the Group, we launched a PSR, allowing existing Shareholders to participate in a fundraise. We are pleased to see this conclude successfully and would like to thank our new and existing Shareholders for taking part. The Board is confident with the future value this earning accretive acquisition will have on the Group and outlook."*

Results from the Offer

At the end of the subscription period, total demand (basic entitlements (*souscriptions à titre irréductible*), excess application facility (*souscriptions à titre réductible*) or unrestricted subscriptions (*souscriptions à titre libre*) amounted to 2,456,286 New Shares applied for at a unit price of €0.40, representing around 125.20% of the maximum number of Shares to be issued under the Offer.

This demand breaks down as follows:

- 328,109 Shares requested under basic entitlements (*souscriptions à titre irréductible*), i.e. a total amount of €131,243.60, representing 16.72% of the total amount of the Offer,

- 592,383 Shares requested under the excess application facility (*souscriptions à titre réductible*), i.e. a total amount of €236,953.20, representing 30.20% of the total amount of the Offer,

- 1,535,794 Shares requested under unrestricted subscriptions (*souscriptions à titre libre*), i.e. a total amount of €614,317.60, representing 78.28% of the total amount of the Offer, including subscription commitments amounting to €595,826[1] secured by the Company prior to the Offer.

[1] Excluding the subscription commitment made under basic entitlement and under the excess application facility by Mr. Jean-Pierre Crinelli (Board member) in the amount of €10,000.

All of the demand under the basic entitlements (*souscriptions à titre irréductible*) and the excess application facility (*souscriptions à titre réductible*) has been satisfied, which represents 46.92% of the amount of the Offer (i.e. €368,196.80).

Among these subscriptions under basic entitlements (*souscriptions à titre irréductible)* and excess application facility (*souscriptions à titre réductible*) is the subscription by Mr. Jean-Pierre Crinelli, a shareholder and member of the Company's Board of Directors, for 25,000 New Shares amounting to €10,000, as provided for in his subscription commitment dated 1 March 2026.

The 1,041,348 New Shares not subscribed for under basic entitlements (*souscriptions à titre irréductible*) and excess application facility (*souscriptions à titre réductible*) representing 53.08% of the amount of the Offer and €416,539.20, were freely distributed and allocated by the Board of directors.

Given the oversubscription, the overall allocation rate for unrestricted subscriptions (*souscriptions à titre libre*) was approximately 67.8%.

Prior to the launch of this Offer, the Company had received subscription commitments (in the form of unrestricted subscription) totalling €595,826.14. This included a commitment of €478,526 from Ardenna PTY Ltd ("Ardenna").

The Board of Directors, on 19 March 2026, decided to allocate all available unsubscribed shares to Ardenna, representing 1,041,348 New Shares, resulting in it holding 1.43% of the Company's enlarged share capital following the Offer. It should be noted that no related governance agreement has been entered into with Ardenna.

Reminder: use of proceeds from the Offer

The net proceeds of the Offer will amount to around €579,736 and will strengthen the Company's balance sheet.

Settlement, delivery and Admission to Trading

Settlement and delivery of the New Shares and their admission to trading on Euronext Growth Paris and AIM are scheduled for on or around 24 March 2026. The New Shares will carry dividend rights, will be immediately fungible with the Company's existing Shares, and will be traded on the same listing line, under the same ISIN code (FR0010397232).

Total Share Capital and Voting Rights:

Following settlement and delivery, the Company's issued share capital will amount to €4,839,205.87 and will be comprised of 72,588,088 ordinary Shares with a par value of €1/15 each.

Impact of the issue on consolidated equity per share:

	Consolidated equity per Share (1)(2)
Before the issue	€0.67
After the issue	€0.66

(1) based on consolidated equity as of 30 June 2025 plus transactions carried out and excluding results since 1 July 2025

(2) it being specified that the Company has not issued any security giving access to share capital

impact of the issue on the situation of a shareholder with 1% of the capital and not subscribing to the Offer

	Percentage of issued share capital

Before the issue	1.00%
After the issue	0.97%

Commitments to Retain Shares and Abstain from Trading

The Company and Ardenna have entered into a lock in arrangement whereby Ardenna has agreed to hold its New Shares for a minimum of 12 months, after which orderly market rules will apply for six months.

Abstention commitments from the Company

None.

Important information:

The Offer did not give rise to a Prospectus approved by the AMF. Nor does this announcement constitute, or form part of, a prospectus *or* a prospectus equivalent document approved by the Financial Conduct Authority ("FCA").

Share codes

• Name: NOVACYT

• ISIN code and share ticker symbol: FR0010397232 - LSE: NCYT / EURONEXT ALNOV

• Listing venue: Euronext Growth Paris

• LEI code: 213800BWAC2BF295EG28

Documents on display

All of the Company's corporate documents that must be made available to Shareholders under French law can be inspected at the Company's headquarters.

The Company reports its financial results in accordance with the requirements of applicable law and regulation. All communications are presented on its website.

For further information, please refer to www.novacyt.com.

Contacts

Novacyt SA	https://novacyt.com/investors
Lyn Rees, Chief Executive Officer	**Via Walbrook PR**
Steve Gibson, Chief Financial Officer	
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)	+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	
Singer Capital Markets (Joint Broker)	+44 (0)20 7496 3000
Phil Davies / James Fischer / Samed Ethemi	
Allegra Finance (French Listing Sponsor) Evelyne Galiatsatos / Yannick Petit	+33 (1) 42 22 10 10 e.galiatsatos@allegrafinance.com / y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) Paul McManus / Lianne Applegarth Alice Woodings	+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654



About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology · genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and

Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

IMPORTANT NOTICE:

This announcement has been issued by and is the sole responsibility of the Company.

References to times in this Announcement are to Paris time unless otherwise stated.

This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Preferential Subscription Rights or New Shares in any jurisdiction, including in or into the United States or any other Restricted Jurisdiction, where the availability of the Offer (and any other transactions contemplated in relation to it) would breach any applicable laws or regulations. Accordingly, subject to certain exceptions, the Offer is not being made in a Restricted Jurisdiction and this announcement will not constitute an offer, or an invitation to apply for, or an offer or an invitation to subscribe for or acquire any Preferential Subscription Rights or New Shares in a Restricted Jurisdiction. No action has been taken by the Company, or SP Angel that would permit an offer of the Preferential Subscription Rights or New Shares or possession or distribution of this announcement or any other publicity material relating to such Preferential Subscription Rights or New Shares in any jurisdiction where action for that purpose is required. Persons receiving this announcement are required to inform themselves about and to observe any such restrictions.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

The distribution of this announcement and the offering, transfer or acquisition of Preferential Subscription Rights or New Shares into jurisdictions other than the United Kingdom and France may be restricted by law, and, therefore, persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws of such jurisdiction. In particular, subject to certain exceptions, this announcement, should not be distributed, forwarded to or transmitted in or into a Restricted Jurisdiction. In the United Kingdom, to the extent this announcement relates to free subscription requests, it is directed only at (a) qualified investors within the meaning of paragraph 15 of Schedule 1 to the Public Offers And Admissions To Trading Regulations 2024/105 who are also (i) persons who fall within the definition of "investment professional" in article 19(5) of the Financial Services And Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "**Order**") or (ii) fall within Article 49(2) of the Order (including certain high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts, or other respective directors, officers or employees as described in Article 49 of the Order), or (b) persons to whom it may otherwise be lawfully communicated.

Recipients of this announcement should conduct their own investigation, evaluation and analysis of the business,

data and property described in this announcement. This announcement does not constitute a recommendation concerning any investor's options with respect to the Offer. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. The contents of this announcement are not to be construed as legal, business, financial or tax advice. Each Shareholder or prospective investor should consult his, her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

The Preferential Subscription Rights and the New Shares to which this announcement relates (the "**Securities**") have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), or under any securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, taken up, renounced or delivered, directly or indirectly, into or within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offer of the Securities in the United States. Subject to certain exceptions, the Securities may not be offered or sold in a Restricted Jurisdiction or to, or for the account or benefit of, any national, resident or citizen of such countries.

SP Angel Corporate Finance LLP ("**SP Angel**"), which is authorised and regulated in the United Kingdom by the FCA, is acting as nominated adviser to the Company in relation to the Offer and is not acting for any other persons in relation to the Offer. SP Angel is acting exclusively for the Company and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be responsible to anyone other than the Company for providing the protections afforded to clients of SP Angel, or for providing advice in relation to the contents of this announcement or any matter referred to in it.

The persons responsible for this announcement are Lyn Rees, Chief Executive Officer and Steve Gibson Chief Financial Officer of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by SP Angel or by any of its affiliates or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

The New Shares will not be admitted to trading on any stock exchange other than the AIM market of the London Stock Exchange and Euronext Growth Paris.

Forward-Looking Statements:

This announcement contains 'forward-looking statements' with respect to the financial condition, results of operations and business of the Company and to certain of the Company's plans and objectives with respect to these items.

Forward-looking statements are sometimes but not always identified by the use of a date in the future or such words as 'anticipates', 'aims', 'due', 'could', 'may', 'should', 'expects', 'believes', 'intends', 'plans', 'targets', 'goal', or 'estimates'. By their very nature forward-looking statements are inherently unpredictable, speculative and involve risk and uncertainty because they relate to events and depend on circumstances that may or will occur in the future. No representation or warranty is made that any forward-looking statement will come to pass.

Neither the Company nor any other person (including SP Angel) intends to update these forward-looking statements. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the AIM Rules for Companies.

You are advised to read this announcement in its entirety for a further discussion of the factors that could affect the Company's future performance. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements in this announcement may not occur. No statement in this announcement is intended as a profit forecast.

Appendix

The following definitions apply throughout this announcement unless the context requires otherwise:

"**AIM**"	AIM, a market operated by the London Stock Exchange
"**AMF**"	the Autorité des marchés financiers, the French financial markets regulator
"**Board**" or "**Directors**"	the board of directors of the Company
"**Euronext Growth Paris**"	Euronext Growth in Paris, a market dedicated to small and midcap companies operated by Euronext
"**New Shares**"	the New Shares issued at the end of the Offer
"**Offer**"	Mean the increase in capital by way of an issue of preferential subscription rights
"**Restricted Jurisdictions**"	United States, Australia, New Zealand, Canada, Japan, or South Africa, or any other jurisdiction in which the availability of the Offer (and any other transaction contemplated in connection therewith) would violate any applicable law or regulation
"**Shares**"	ordinary Shares of 1/15th of one Euro each in the share capital of the Company

.	**Details of the person discharging managerial responsibilities/person closely associated**	
a)	Name:	1) Mr Jean-Pierre Crinelli
2.	**Reason for the notification**	
a)	Position/status:	1) Non-Executive Director
b)	Initial notification/Amendment:	Initial notification
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name:	Novacyt S.A.
b)	LEI:	**213800BWAC2BF295EG28**
4.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument: Identification code:	New shares of EUR1/15TH each FR0010397232
b)	Nature of the transaction:	Purchase of shares pursuant to a Preferential Subscription Rights issue on Euronext
c)	Price(s) and volume(s):	1) 25,000 Shares at EUR 0.40
d)	Aggregated information: Aggregated volume: Price:	as in 4 c) above 25,000 EUR 0.40
e)	Date of the transaction:	19 March 2026
f)	Place of the transaction:	Outside of Trading Venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUKRRRNAUOAUR